Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The conformation of this loop is virtually identical in the three HDLP structures (Finnin et al., 1999), suggesting that the surface of HDLP is less malleable than that of HDAC8 around the binding site pocket.”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“The apparent reduced flexibility in the HDLP surface may also explain why it is less efficient in histone deacetylase assays (Finnin et al., 1999).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“Finnin et al. (1999) have suggested that H143 protonates the lysine after the carbon-nitrogen scissile bond breaks.”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Finnin et al., 1999
In the citing paper
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Finnin et al., 1999
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures
Kraulis, P. J. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891004399 · Cited by 14,085
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
[26] Raster3D: Photorealistic molecular graphics
Merritt, E. A., & Bacon, D. J. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)77028-9 · Cited by 3,739
The relation between the divergence of sequence and structure in proteins.
Chothia, C., & Lesk, A. M. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04288.x · Cited by 2,458
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815
The complete genome of the hyperthermophilic bacterium Aquifex aeolicus
Deckert, G., Warren, P. V., Gaasterland, T., Young, W. G., Lenox, A. L., Graham, D. E., Overbeek, R., Snead, M. A., Keller, M., Aujay, M., et al. (1998) · Nature · doi:10.1038/32831 · Cited by 1,097
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citation
Research works printed but not linked: 2
- Cohen,L. A. et al. Inhibition of N-methylnitrosourea-induced tumours by the cytodifferentiating agent, suberanilohydroxamic acid (SAHA). Proc. AACR 39, 108, abstr. 736 (1998).
- Desai,D., El-Bayoumy,K. & Amin,S. Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylinitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Proc. AACR 40, 2396, abstr. 362 (1999).
Cited by
Items 501–600 of 1,007
Imai, T., Adachi, S., Nishijo, K., Ohgushi, M., Okada, M., Yasumi, T., Watanabe, K.-I., Nishikomori, R., Nakayama, T., Yonehara, S., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207184 · Cited by 68
Colletti, S. L., Myers, R. W., Darkin‐Rattray, S. J., Gurnett, A. M., Dulski, P. M., Galuska, S., Allocco, J., Ayer, M. B., Li, C., Lim, J., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00604-1 · Cited by 68
Andreoli, F., Barbosa, A. J. M., Parenti, M. D., & Río, A. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581918 · Cited by 68
Kahnberg, P., Lucke, A. J., Glenn, M. P., Boyle, G. M., Tyndall, J. D. A., Parsons, P. G., & Fairlie, D. P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050214x · Cited by 68
Scott, G. K., Marden, C. M., Xu, F., Kirk, L., & Benz, C. C. (2002) · Molecular Cancer Therapeutics · Cited by 68
Hsi, L. C., Xi, X., Lotan, R., Shureiqi, I., & Lippman, S. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1867 · Cited by 68
General Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67
HDAC genes play distinct and redundant roles in Cryptococcus neoformans virulence
Brandão, F., Esher, S. K., Ost, K. S., Pianalto, K., Nichols, C. B., Fernandes, L., Bocca, A. L., Poças-Fonseca, M. J., & Alspaugh, J. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21965-y · Cited by 67
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors
Chen, B., Petukhov, P. A., Jung, M., Velena, A., Eliseeva, E. D., Dritschilo, A., & Kozikowski, A. P. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.006 · Cited by 67
Riester, D., Wegener, D., Hildmann, C., & Schwienhorst, A. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.155 · Cited by 67
Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors
Schroeder, T. M., Nair, A., Staggs, R. A., Lamblin, A. F., & Westendorf, J. J. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-362 · Cited by 67
Mai, A., Massa, S., Cerbara, I., Valente, S., Ragno, R., Bottoni, P., Scatena, R., Loidl, P., & Brosch, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030990+ · Cited by 67
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
“1Comprehensive Cancer Imaging Centre, Department of Surgery and Cancer Faculty of Medicine, Imperial College London,”
BackgroundCyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases
Nishino, N., Jose, B., Okamura, S., Ebisusaki, S., Kato, T., Sumida, Y., & Yoshida, M. (2003) · Organic Letters · doi:10.1021/ol036098e · Cited by 66
New method to detect histone acetylation levels by flow cytometry
Ronzoni, S., Faretta, M., Ballarini, M., Pelicci, P., & Minucci, S. (2005) · Cytometry Part A · doi:10.1002/cyto.a.20151 · Cited by 66
Ballante, F., & Marshall, G. R. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00603 · Cited by 66
Differential Properties of Transcriptional Complexes Formed by the CoREST Family
Barrios, Á. P., Gómez, A. V., Sáez, J. E., Ciossani, G., Toffolo, E., Battaglioli, E., Mattevi, A., & Andrés, M. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00083-14 · Cited by 66
Regulating Chromatin by Histone Acetylation
Steunou, A., Rossetto, D., & Côté, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8624-4_4 · Cited by 66
Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
Han, Y., Nie, J., Wang, D. W., & Li, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.931475 · Cited by 66
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
Cooper, A. L., Greenberg, V. L., Lancaster, P. S., van Nagell, J. R., Zimmer, S. G., & Modesitt, S. C. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.09.011 · Cited by 65
Signal transduction pathways and the modification of chromatin structure
Davie, J., & Spencer, V. A. (2000) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(00)65008-0 · Cited by 65
Computational Exploration of Zinc Binding Groups for HDAC Inhibition
Chen, K., Xu, L., & Wiest, O. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400406g · Cited by 65
Han, J. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl389 · Cited by 65
Xu, S., De Veirman, K., Evans, H., Santini, G. C., Vande Broek, I., Leleu, X., De Becker, A., Van Camp, B., Croucher, P., Vanderkerken, K., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.182 · Cited by 64
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6
Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64
Papeleu, P., Vanhaecke, T., Elaut, G., Vinken, M., Henkens, T., Snykers, S., & Rogiers, V. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935639 · Cited by 64
Non-Peptide Macrocyclic Histone Deacetylase Inhibitors
Oyelere, A. K., Chen, P. C., Guerrant, W., Mwakwari, S. C., Hood, R., Zhang, Y., & Fan, Y. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801128g · Cited by 64
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
Auzzas, L., Larsson, A., Matera, R., Baraldi, A., Deschênes-Simard, B., Giannini, G., Cabri, W., Battistuzzi, G., Gallo, G., Ciacci, A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101092u · Cited by 63
Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors
Suzuki, T. (2009) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.57.897 · Cited by 63
HDAC Inhibitors and Cancer Therapy
Atadja, P. W. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8989-5_9 · Cited by 63
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Frühauf, A., & Meyer‐Almes, F. (2021) · Molecules · doi:10.3390/molecules26175151 · Cited by 63
Jackman, J. E., Raetz, C. R. H., & Fierke, C. A. (2000) · Biochemistry · doi:10.1021/bi001872g · Cited by 63
The therapeutic uses of chromatin-modifying agents
Mai, A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.835 · Cited by 63
Regenerative medicine and tissue engineering in orthopaedic surgery
Ivković, A., Marijanović, I., Hudetz, D., Porter, R. M., Pecina, M. M., & Evans, C. H. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e299 · Cited by 63
Premkumar, D. R., Jane, E. P., Agostino, N. R., DiDomenico, J. D., & Pollack, I. F. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21835 · Cited by 62
Targeting Epigenetic Mechanisms: Potential of Natural Products in Cancer Chemoprevention
Hauser, A., & Jung, M. (2008) · Planta Medica · doi:10.1055/s-2008-1081347 · Cited by 62
Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A
Zhong, S., Goto, H., Inagaki, M., & Dong, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206507 · Cited by 62
Role of Natural Products in Modulating Histone Deacetylases in Cancer
Mérarchi, M., Sethi, G., Shanmugam, M. K., Fan, L., Arfuso, F., & Ahn, K. S. (2019) · Molecules · doi:10.3390/molecules24061047 · Cited by 62
Jursic, B. S., & Neumann, D. M. (2001) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)01830-5 · Cited by 62
Image-Guided Synthesis Reveals Potent Blood-Brain Barrier Permeable Histone Deacetylase Inhibitors
Seo, Y. J., Kang, Y., Muench, L., Reid, A., Caesar, S., Jean, L., Wagner, F., Holson, E., Haggarty, S. J., Weiss, P., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500021p · Cited by 61
Inhibition and Mechanism of HDAC8 Revisited
Chen, K., Zhang, X., Wu, Y.-D., & Wiest, O. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501548p · Cited by 61
Regulation of vitamin metabolism by p53 and p63 in development and cancer
Zhou, H., & van Bokhoven, H. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12591 · Cited by 61
Meinke, P. T., Colletti, S. L., Doss, G. A., Myers, R. W., Gurnett, A. M., Dulski, P. M., Darkin‐Rattray, S. J., Allocco, J., Galuska, S., Schmatz, D. M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001976 · Cited by 61
Mai, A., Massa, S., Ragno, R., Esposito, M., Sbardella, G., Nocca, G., Scatena, R., Jesacher, F., Loidl, P., & Brosch, G. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011088+ · Cited by 61
Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling
Chen, Y., Jiang, Y., Zhou, J., Yu, Q., & You, Q. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.10.007 · Cited by 61
Yang, Y., Balch, C., Kulp, S. K., Mand, M. R., Nephew, K. P., & Chen, C. (2009) · Neoplasia · doi:10.1593/neo.09204 · Cited by 61
Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug
Brioschi, A., Zara, G. P., Calderoni, S., Gasco, M. R., & Mauro, A. (2008) · Molecules · doi:10.3390/molecules13020230 · Cited by 61
Becher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60
DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors
Vanommeslaeghe, K., Loverix, S., Geerlings, P., & Tourwé, D. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.06.009 · Cited by 60
Papeleu, P., Loyer, P., Vanhaecke, T., Elaut, G., Geerts, A. E., Guguen‐Guillouzo, C., & Rogiers, V. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00288-5 · Cited by 60
Vergani, B., Sandrone, G., Marchini, M., Ripamonti, C., Cellupica, E., Galbiati, E., Caprini, G., Pavich, G., Porro, G., Rocchio, I., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01194 · Cited by 60
Chromatin Modifications as Targets for New Anticancer Drugs
Schäfer, S., & Jung, M. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200500984 · Cited by 60
Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing
Ahlenstiel, C., Mendez, C., Lim, S. T. H., Marks, K., Turville, S., Cooper, D. A., Kelleher, A. D., & Suzuki, K. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.31 · Cited by 60
Shinji, C., Maeda, S., Imai, K., Yoshida, M., Hashimoto, Y., & Miyachi, H. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.07.008 · Cited by 60
Humphrey, G. W., Wang, Y., Hirai, T. H., Padmanabhan, R., Panchision, D. M., Newell, L. F., McKay, R. D. G., & Howard, B. H. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00232.x · Cited by 60
Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors
Mai, A., Massa, S., Rotili, D., Simeoni, S., Ragno, R., Botta, G., Nebbioso, A., Miceli, M., Altucci, L., & Brosch, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0605536 · Cited by 60
Wu, T., Zhao, Y., Zhang, X., Wang, Y., Chen, Q., Zhang, M., Sheng, H., Zhang, Y., Guo, J., Li, J., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.70048 · Cited by 60
Regulation of inflammatory responses by pH-dependent transcriptional condensates
Wu, Z., Pope, S. D., Ahmed, N. S., Leung, D. L., Hong, Y., Hajjar, S., Krabak, C., Zhong, Z., Raghunathan, K., Yue, Q., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.033 · Cited by 60
Sleeping Beauty Transposase Has an Affinity for Heterochromatin Conformation
Ikeda, R., Kokubu, C., Yusa, K., Keng, V. W., Horie, K., & Takeda, J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01500-06 · Cited by 60
Repurposing Vorinostat for the Treatment of Disorders Affecting Brain
Athira, K. V., Sadanandan, P., & Chakravarty, S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08660-4 · Cited by 59
Mai, A., Massa, S., Pezzi, R., Rotili, D., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034167p · Cited by 59
Histone deacetylase inhibitors for epigenetic therapy of cancer
Monneret, C. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328012a5db · Cited by 59
HDACi: Cellular Effects, Opportunities for Restorative Dentistry
Duncan, H. F., Smith, A. J., Fleming, G. J. P., & Cooper, P. R. (2011) · Journal of Dental Research · doi:10.1177/0022034511406919 · Cited by 59
Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer
Catalano, M. G., Fortunati, N., & Boccuzzi, G. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00040 · Cited by 59
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
UM171 glues asymmetric CRL3–HDAC1/2 assembly to degrade CoREST corepressors
Yeo, M. J. R., Zhang, O., Xie, X., Nam, E., Payne, N. C., Gosavi, P. M., Kwok, H. S., Iram, I., Lee, C., Li, J., et al. (2025) · Nature · doi:10.1038/s41586-024-08532-4 · Cited by 58
Weerasinghe, S. V. W., Estiu, G., Wiest, O., & Pflum, M. K. H. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800081j · Cited by 58
Vanhaecke, T., Henkens, T., Kass, G. E. N., & Rogiers, V. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.022 · Cited by 58
Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents
Nam, N., Huong, T. L., Dung, D. T. M., Dung, P. T. P., Oanh, D. T. K., Quyen, D., Thảo, L. T. P., Park, S. H., Kim, K. R., Han, B. W., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.045 · Cited by 58
Zhang, J., Kan, S., Huang, B., Hao, Z., Mak, T. W., & Zhong, Q. (2011) · Genes & Development · doi:10.1101/gad.170605.111 · Cited by 58
Lim, E. J., Lu, T. X., Blanchard, C., & Rothenberg, M. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.210724 · Cited by 58
Drummond, D. C., Marx, C., Guo, Z., Scott, G. K., Noble, C. O., Wang, D., Pallavicini, M. G., Park, J. W., Kirpotin, D. B., & Benz, C. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2445 · Cited by 58
Ronan, J. L., Kadi, N., McMahon, S. A., Naismith, J. H., Alkhalaf, L. M., & Challis, G. L. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0068 · Cited by 58
Guo, Y., Xiao, J., Guo, Z., Chu, F., Cheng, Y.-H., & Wu, S. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.05.016 · Cited by 58
Wu, G., Nan, C., Rollo, J. C., Huang, X., & Tian, J. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-16 · Cited by 57
Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents
Ye, R., Tan, C., Chen, B.-C., Li, R., & Mao, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00402 · Cited by 57
Bieliauskas, A. V., Weerasinghe, S. V. W., & Pflum, M. K. H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.117 · Cited by 57
Sampathkumar, S., Jones, M. B., Meledeo, M. A., Campbell, C. T., Choi, S. S., Hida, K., Gomutputra, P., Sheh, A., Gilmartin, T., Head, S. R., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.016 · Cited by 57
Charrier, C., Clarhaut, J. A., Gesson, J., Estiu, G. L., Wiest, O., Roche, J., & Bertrand, P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002439 · Cited by 57
Comparative and pharmacophore model for deacetylase SIRT1
Huhtiniemi, T., Wittekindt, C., Laitinen, T., Leppänen, J., Salminen, A., Poso, A., & Lahtela-Kakkonen, M. K. (2006) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9084-9 · Cited by 57
Histone Deacetylase Inhibitors in Cancer Therapy
Fouladi, M. (2006) · Cancer Investigation · doi:10.1080/07357900600814979 · Cited by 57
Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Budillon, A., Gennaro, E. D., Bruzzese, F., Rocco, M., Manzo, G., & Caraglia, M. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207780832450 · Cited by 57
Structural Basis for Ceramide Recognition and Hydrolysis by Human Neutral Ceramidase
Airola, M. V., Allen, W. J., Pulkoski‐Gross, M. J., Obeid, L. M., Rizzo, R. C., & Hannun, Y. A. (2015) · Structure · doi:10.1016/j.str.2015.06.013 · Cited by 57
Lee, S., Shinji, C., Ogura, K., Shimizu, M., Maeda, S., Sato, M., Yoshida, M., Hashimoto, Y., & Miyachi, H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.038 · Cited by 56
Vanommeslaeghe, K., Proft, F. D., Loverix, S., Tourwé, D., & Geerlings, P. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.001 · Cited by 56
Phosphorus-Based SAHA Analogues as Histone Deacetylase Inhibitors
Kapustin, G. V., Fejér, G., Gronlund, J. L., McCafferty, D. G., Seto, E., & Etzkorn, F. A. (2003) · Organic Letters · doi:10.1021/ol035056n · Cited by 56
Choong, C., Sasaki, T., Hayakawa, H., Yasuda, T., Baba, K., Hirata, Y., Uesato, S., & Mochizuki, H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.001 · Cited by 56
Takigawa-Imamura, H., Sekine, T., Murata, M., Takayama, K., Nakazawa, K., & Nakagawa, J. (2003) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.67.1499 · Cited by 56
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2
Scognamiglio, A., Nebbioso, A., Manzo, F., Valente, S., Mai, A., & Altucci, L. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.07.007 · Cited by 56
Heterocyclic ketones as inhibitors of histone deacetylase
Vasudevan, A., Ji, Z., Frey, R. R., Wada, C. K., Steinman, D. H., Heyman, H. R., Guo, Y. P., Curtin, M. L., Guo, J., Li, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.007 · Cited by 56
The use of atomic intrinsic polarizabilities in the evaluation of the dispersion energy
Olasz, A., Vanommeslaeghe, K., Krishtal, A., Veszprémi, T., Alsenoy, C. V., & Geerlings, P. (2007) · The Journal of Chemical Physics · doi:10.1063/1.2805391 · Cited by 56
Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure
Evans, L. W., & Ferguson, B. S. (2018) · Nutrients · doi:10.3390/nu10081120 · Cited by 56
Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Gao, Y., & Tollefsbol, T. O. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150420102641 · Cited by 56
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
Jayathilaka, N., Han, A., Gaffney, K. J., Dey, R., Jarusiewicz, J. A., Noridomi, K., Philips, M. A., Lei, X., He, J., Ye, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks189 · Cited by 56
Ragno, R., Mai, A., Massa, S., Cerbara, I., Valente, S., Bottoni, P., Scatena, R., Jesacher, F., Loidl, P., & Brosch, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031036f · Cited by 56
Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group
Wu, T. Y.-H., Hassig, C. A., Wu, Y., Ding, S., & Schultz, P. G. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.055 · Cited by 56
Ding, C., Chen, S., Zhang, C., Hu, G., Zhang, W., Li, L., Chen, Y., Tan, C., & Jiang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.006 · Cited by 55
Discovery of HDAC Inhibitors That Lack an Active Site Zn2+-Binding Functional Group
Vickers, C. J., Olsen, C. A., Leman, L. J., & Ghadiri, M. R. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300081u · Cited by 55
Histone deacetylase 10, a potential epigenetic target for therapy
Cheng, F., Zheng, B., Wang, J., Zhao, G., Yao, Z., Niu, Z., & He, W. (2021) · Bioscience Reports · doi:10.1042/bsr20210462 · Cited by 55
Metadata
- Authors
- Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Pavletich, Nikola P.
- Venue
- Nature
- Published
- 1999-09
- Volume
- 401
- Issue
- 6749
- Pages
- 188-193
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2135830745
- Cited by
- 1,714
- References
- 28
- Citations by year
- 2026: 39 · 2025: 48 · 2024: 40 · 2023: 55 · 2022: 28 · 2021: 66 · 2020: 62 · 2019: 50 · 2018: 52 · 2017: 70 · 2016: 68 · 2015: 74 · 2014: 67 · 2013: 78 · 2012: 82
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, trichostatin A, vorinostat, Aquifex aeolicus, crystal structure, catalytic site, zinc binding site, hyperthermophilic bacteria, anticancer agents, promyelocytic leukemia
- MeSH terms
- Vorinostat, Amino Acid Sequence, Enzyme Inhibitors, Escherichia coli, Histone Deacetylases, Humans, Hydroxamic Acids, Models, Molecular, Molecular Sequence Data, Protein Binding, Protein Conformation, Recombinant Fusion Proteins, Zinc, Gram-Negative Aerobic Rods and Cocci, Sequence Homology, Amino Acid, Crystallography, X-Ray, Catalytic Domain, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.